The Cdc25A protein phosphatase drives cell-cycle transitions by activating cyclin-dependent protein kinases. Failure to regulate Cdc25A leads to deregulated cellcycle progression, bypass of cell-cycle checkpoints and genome instability. Ubiquitin-mediated proteolysis has an important role in balancing Cdc25A levels. Cdc25A contains a DS 82 G motif whose phosphorylation is targeted by b-TrCP E3 ligase during interphase. Targeting b-TrCP to Cdc25A requires phosphorylation of serines 79 (S79) and 82 (S82). Here, we report that casein kinase 1 a (CK1a) phosphorylates Cdc25A on both S79 and S82 in a hierarchical manner requiring prior phosphorylation of S76 by Chk1 or GSK-3b. This facilitates b-TrCP binding and ubiquitin-mediated proteolysis of Cdc25A throughout interphase and after exposure to genotoxic stress. The priming of Cdc25A by at least three kinases (Chk1, GSK-3b, CK1a), some of which also require priming, ensures diverse extra-and intracellular signals interface with Cdc25A to precisely control cell division.
Introduction
The Cdc25A protein phosphatase is one of three Cdc25 family members in mammals. Cdc25A positively regulates both early and late cell-cycle transitions by activating cyclin-dependent protein kinases (Boutros et al., 2006) . The overall abundance and activity of Cdc25A is regulated throughout the cell division cycle by transcriptional and posttranscriptional mechanisms. Posttranscriptional mechanisms include reversible phosphorylation, protein-protein interactions, ubiquitinmediated proteolysis and intracellular compartmentalization (Bernardi et al., 2000; Chen et al., 2003; Busino et al., 2004; Boutros et al., 2006) . Cdc25A protein levels peak in mitosis and Cdc25A is degraded by the APC/ C Cdh1 E3 ligase as cells exit mitosis (Donzelli et al., 2002; Busino et al., 2004) . Cdc25A transcription is activated by E2F/c-Myc in the G1 phase of the cell cycle and Cdc25A levels begin to rise in mid-to late-G1 (Galaktionov et al., 1996; Vigo et al., 1999) . However, the accumulation of Cdc25A through enhanced transcription is counterbalanced by its ubiquitin-mediated proteolysis, which occurs throughout interphase and is mediated by the b-TrCP E3 ligase (Donzelli et al., 2002; Busino et al., 2003 Busino et al., , 2004 Jin et al., 2003; Ray et al., 2005) . Cdc25A is also rapidly targeted for ubiquitin-mediated proteolysis when cells experience genotoxic or replication stress and failure to degrade Cdc25A during a checkpoint response leads to bypass of the S-and G2-checkpoints (Mailand et al., 2000; Molinari et al., 2000; Falck et al., 2001; Zhao et al., 2002; Hassepass et al., 2003) .
The importance of balancing Cdc25A accumulation with its destruction is underscored by the observation that overproduction of Cdc25A results in accelerated S-phase and mitotic entry leading to genome instability (Blomberg and Hoffman, 1999; Mailand et al., 2000; Molinari et al., 2000; Bartek and Lukas, 2001; Falck et al., 2001; Zhao et al., 2002) . In addition, overproduction of Cdc25A is observed in many human cancers and Cdc25A has been shown to be rate limiting in a mouse model of tumorigenesis (Kristjansdottir and Rudolph, 2004; Ray and Kiyokawa, 2008) . Furthermore, posttranscriptional mechanisms account for Cdc25A overproduction in several breast cancer cell lines, suggesting that proteins regulating Cdc25A destruction could be derailed in these cancers (Loffler et al., 2003) . GSK-3b regulates Cdc25A destruction during early cell-cycle phases by phosphorylating serine 76 (S76) and a correlation between Cdc25A overproduction and GSK-3b inactivation is observed in human tumor tissues, indicating that GSK-3b inactivation may account for Cdc25A overproduction in a subset of human tumors (Kang et al., 2008) .
During interphase, b-TrCP-mediated Cdc25A destruction requires S82 within the DSG motif to be phosphorylated (Busino et al., 2003; Jin et al., 2003) . Phosphorylation of DSG motif facilitates Cdc25A interactions with b-TrCP. Phosphorylation of serine and threonine residues neighboring the DSG motif including S76, S79 and T80 has also been reported to be important for Cdc25A ubiquitination by promoting phosphorylation of S82 (Goloudina et al., 2003; Hassepass et al., 2003; Jin et al., 2003; Donzelli et al., 2004; Kang et al., 2008) . S76 phosphorylation is mediated by GSK-3b during early cell-cycle phases and by Chk1 during S and G2 phases (Zhao et al., 2002; Goloudina et al., 2003; Hassepass et al., 2003; Kang et al., 2008) . Whereas Chk1 does not require a priming phosphorylation site, GSK-3b requires that Cdc25A first be phosphorylated on T80, which can be catalyzed by Plk3 (Kang et al., 2008) . The protein kinases that phosphorylate Cdc25A on S79 and S82, the key residues that mediate b-TrCP binding, have not been identified. Here, we show that casein kinase 1 a (CK1a) mediates interactions between b-TrCP and Cdc25A in vivo by phosphorylating Cdc25A on both S79 and S82 in a hierarchical manner that requires prior phosphorylation of S76.
Results
Validation of Cdc25A-FLuc reporter Our original aim was to carry out high-throughput screens using siRNAs against the human kinome to identify novel protein kinases that regulate Cdc25A stability and, in particular, to identify the protein kinase that phosphorylates Cdc25A on S82. With this aim in mind, stable cell lines that inducibly express a fusion protein between human Cdc25A and firefly luciferase (Cdc25A-FLuc) were generated to enable direct realtime monitoring of Cdc25A protein levels in cells. The promoter driving Cdc25A-FLuc expression contains a tetracycline response element regulated by reverse tetracycline-controlled transactivator and doxycycline (Dox), a tetracycline derivative. Expression of the Cdc25A-FLuc fusion protein was induced by addition of Dox to the culture media, and the level of Cdc25A-FLuc protein correlated with its luciferase activity (Figures 1a and b ). Furthermore, Cdc25A-FLuc protein levels were stabilized in cells incubated with either a proteosome inhibitor (MG132) or Chk1 inhibitors (UCN-01, Go¨6976 and AZD7762) ( Figure 1c and data not shown). These data suggested that the Cdc25A-FLuc fusion protein was a valid substrate with which to identify novel Cdc25A regulatory kinases. As further controls, cells were incubated with siRNAs specific for protein kinases known to negatively regulate Cdc25A stability including Chk1 and GSK-3b ( Figure 2a ). As expected, stabilization of the Cdc25A-FLuc reporter protein was observed under these conditions. As a Figure 1 Validation of Cdc25A-FLuc fusion reporter. (a) HeLa Tet-on Cdc25A-FLuc cells were cultured in the presence of 2 mg/ml doxycycline (Dox) for 16 h followed by D-Luciferin for 10 min. Cells were imaged using a charge-coupled device (CCD) camera-based bioluminescence imaging system (IVIS 100; Caliper). The color overlay on the images represents the photons/s/cm 2 / steradian (p/s/cm 2 /sr) as indicated by the color scale next to the images. Cells were harvested immediately after imaging and analyzed for the Cdc25A-FLuc reporter protein by western blotting using a Cdc25A-specific antibody. Lysates were probed for b-Catenin as a loading control. (b) HeLa Tet-on Cdc25A-FLuc cells were incubated in the culture media containing 2 mg/ml Dox for 13 or 15 h. Cells were then cultured in the absence of Dox for the indicated times and analyzed for Cdc25A-FLuc by western blotting or for luciferase activity by bioluminescence imaging. Lysates were probed for actin as a loading control. (c) HeLa Tet-on Cdc25A-FLuc cells were cultured in media containing 2 mg/ml Dox. After 16 h, the culture media was removed and cells were cultured in Dox-free media containing 10 mg/ml cycloheximide and either MG132 (50 mM) or UCN-01 (500 nM) for 90 min, D-Luciferin was then added and cells were imaged 10 min later. Immediately after imaging, cells were lysed for western blotting. Quantification of bioluminescence signal plotted as mean ± s.e.m. (n ¼ 3). P-values from Student's t-test are shown when significantly different from control. Asterisks indicate significant P-values (**o0.01;***o0.001).
Hierarchical phosphorylation of Cdc25A by CK1a Y Honaker and H Piwnica-Worms negative control, cells were incubated with siRNAs specific for CK1a as CK1 inhibition was reported to have no effect on Cdc25A stability (Jin et al., 2003) . Unexpectedly, enhanced bioluminescence indicative of Cdc25A-FLuc stabilization was observed in cells treated with CK1a-specific siRNAs (Figure 2a ). CK1 had been ruled out as a potential Cdc25A-regulatory kinase based on experiments performed with the casein kinase I inhibitors CKI-7 and IC261 (Jin et al., 2003) .
Therefore, we tested CK1 inhibitors for their ability to stabilize Cdc25A-FLuc protein. D4476 was chosen because it is a more potent and selective CK1 inhibitor than either IC261 or CKI-7 (Rena et al., 2004; Bain et al., 2007) and IC261 was also tested. IC261 shows selectivity for CK1d and CK1e over CK1a (Behrend et al., 2000) . As seen in Figure 2b , enhanced bioluminescence indicative of Cdc25A-FLuc stabilization was observed in D4476-treated cells but not in IC261-treated cells. These results suggest that CK1 family members other than CK1d and CK1e may function to negatively regulate Cdc25A stability in vivo. To test this hypothesis more directly, we monitored levels of endogenous Cdc25A in CK1a-depleted cells. As seen in Figure 2c , an approximate twofold increase in endogenous Cdc25A protein was observed in CK1a-depleted cells. In addition, the half-life of Cdc25A was increased in cells knocked down for CK1a ( Figure 2d ). In contrast, endogenous Cdc25A was not stabilized in cells depleted for CK1d, CK1e or CK1g1 (Supplementary Figure S3 ).
CK1 phosphorylates Cdc25A on S82 in vitro A domain bordered by amino acids 76-88 has been shown to regulate the ubiquitin-mediated proteolysis of Cdc25A during interphase and to contain a novel b-TrCP recognition motif or phosphodegron ( Figure 3a ) (Busino et al., 2003; Jin et al., 2003) . The novel phosphodegron in Cdc25A uses pS79 and pS82, rather than pS82 and pS88, for b-TrCP binding (Jin et al., 2003) . Six potential phosphorylation sites reside within this 14-amino-acid domain. Cdc25A has been shown to be phosphorylated on S76 and T80 and phosphorylation of S79, S82 and S88 have been inferred based on mutagenesis studies and phosphopeptide competition experiments (Goloudina et al., 2003; Hassepass et al., 2003; Jin et al., 2003; Kang et al., 2008) . Antibodies (a) HeLa Tet-on Cdc25A-FLuc cells were mock transfected or transfected with control siRNA (Scr) or siRNAs specific for Chk1, GSK-3b or CK1a for 48 h and then cultured in the presence of 2 mg/ml Dox for an additional 16 h. Cells were incubated with D-Luciferin and imaged 10 min later. Quantification of bioluminescence signal plotted as mean ± s.e.m. (n ¼ 3). P-values from Student's t-test are shown when significantly different from control. Asterisks indicate significant P-values (**o0.01;***o0.001). (b) HeLa Tet-on Cdc25A-FLuc cells were cultured in media containing 2 mg/ml Dox. After 16 h, the culture media was removed and cells were cultured in Dox-free media containing 10 mg/ml cycloheximide and either DMSO, UCN-01 (500 nM), D4476 (75 mM) or IC261 (50 mM) for 1 h, D-Luciferin was then added and cells were imaged 10 min later. Quantification of bioluminescence signal was plotted as mean±s.e.m. (n ¼ 3). P-values from Student's t-test are shown when significantly different from control. Asterisks indicate significant P-values (***o0.001). The color overlay on the images represents the photons/s/cm 2 /steradian (p/s/cm 2 /sr) as indicated by the color scale next to the images. (c) HeLa cells were transfected with control siRNA (Ctrl) or siRNA targeting CK1a for 48 h followed by western blotting for the indicated proteins. (d) HeLa cells were transfected with control-(Ctrl) or CK1a-siRNA for 48 h followed by cycloheximide (CHX; 10 mg/ml) for the indicated times. Proteins were resolved by SDS-PAGE and analyzed by western blotting. A representative western blot is shown and quantification from three independent experiments is shown graphically. Standard error of the mean is shown as error bars along the y axis. specific for known and predicted phosphorylation sites were generated ( Figure 3b ) and used to show that Cdc25A is phosphorylated on S79, S82 and S88 in addition to S76 and T80 ( Figure 3c ). Specificity was verified by testing each phospho-specific antibody for its ability to recognize WT Cdc25A but not the corresponding alanine-mutant protein by western blotting (Figure 3c ). It was also determined that neither S79 phosphorylation nor substitution of alanine for serine at position 79 interfered with the ability of the phospho-S82 antibody to recognize Cdc25A when it is phosphorylated on S82 (Supplementary Figure S1 ) and neither S76 phosphorylation nor substitution of alanine for serine at position 76 interfered with the ability of the phospho-S79 antibody to recognize Cdc25A when it is phosphorylated on S79 (Supplementary Figure S2) .
Kinase assays were performed to determine if CK1 is able to directly phosphorylate Cdc25A on S82 in vitro ( Figure 4a ). Wild-type Cdc25A and phosphorylationsite mutants were purified as GST fusion proteins from bacteria and incubated with purified CK1. Phosphorylation of S82 was monitored by western blotting with the phospho-S82 antibody. As seen in Figure 4a , CK1 phosphorylated Cdc25A on S82 (lane 1) and substitution of alanine for serine at position 88 did not effect S82 phosphorylation (lane 3).
CK1 regulates phosphorylation of Cdc25A on S82 in vivo If CK1a phosphorylates Cdc25A on S82 in vivo, changes in level or activity of CK1a should affect S82 phosphorylation. Indeed, enhanced S82 phosphorylation of endogenous ( Figure 4b ) and ectopic (Supplementary Figure S4a ) Cdc25A was observed in cells overproducing CK1a. Overproduction of CK1a did not enhance phosphorylation of Cdc25A on S76, T80, S88 or S123 (data not shown). Reduced S82 phosphorylation was detected in cells depleted for CK1a (Supplementary Figure S4b ). Similarly, inhibition of CK1 kinase activity also decreased S82 phosphorylation of Cdc25A (Supplementary Figure S4c ). Whereas 50 mM D4476 was sufficient to reduce S82 phosphorylation in vivo, concentrations of IC261 as high as 100 mM had minimal effects on S82 phosphorylation. Conversely, S82 phosphorylation was not affected in cells treated with either TBB (CK2 inhibitor) or KN-93 (CaMKII inhibitor) (Supplementary Figure S4d) .
S82 phosphorylation has been shown to mediate b-TrCP binding, which in turn, promotes ubiquitinmediated proteolysis of Cdc25A (Busino et al., 2003; Jin et al., 2003) . Thus, CK1a overproduction was expected to enhance interactions between Cdc25A and b-TrCP. As seen in Figure 4c , an increase in association between b-TrCP and Cdc25A was observed in CK1a-overexpressing cells comparing lanes 3 and 4. Enhanced b-TrCP binding is predicted to promote Cdc25A turnover and indeed, lower levels of Cdc25A were also observed in CK1a-overproducing cells ( Figure 4d ) and CK1a knockdown increased the half-life of Cdc25A (Figure 2d ). Taken together, these results provide strong evidence that CK1a directly regulates phosphorylation of Cdc25A on S82 and promotes b-TrCP binding in vivo.
CK1 regulates S82 phosphorylation after exposure to genotoxic stress Ionizing radiation has been shown to increase the phosphorylation of Cdc25A on S82 (Busino et al., 2003) , which in turn promotes Cdc25A proteolysis. We asked if inhibition of CK1 would reduce S82 phosphorylation and extend the half-life of Cdc25A in irradiated cells. As seen in Figure 4e , S82 phosphorylation of Cdc25A was significantly reduced after D4476 treatment in both mock-irradiated (lane 2) and irradiated (lane 4) cells. D4476 did not affect levels of S76 or S88 phosphorylation under either condition. These experiments were conducted in the absence of cycloheximide, so levels of ectopic Cdc25A did not change significantly on irradiation. In the presence of cycloheximide, D4476 was observed to extend the half-life of both endogenous and ectopic Cdc25A (Cdc25A-FLuc) in irradiated cells (Figure 4f ). These results indicate that CK1 regulates S82 phosphorylation in normal cycling cells and in cells experiencing genotoxic stress. Hierarchical phosphorylation of Cdc25A by CK1a Y Honaker and H Piwnica-Worms CK1 phosphorylates S79 to prime for subsequent phosphorylation of S82 CK1, similar to GSK-3b, requires a priming phosphate in its substrates, which is introduced by a priming kinase. CK1 often phosphorylates the serine residue (underlined) in the motif pS-X-X-S where pS is phosphoserine (Flotow et al., 1990) . Phosphorylation of S79 could serve as a priming phosphorylation site for S82 phosphorylation and we determined that S79 is phosphorylated in vivo (Figure 3c ). Interestingly, sequences inclusive of and surrounding S79 also con-form to one of the CK1 phosphorylation consensus motifs (Figure 3a) . Thus, kinase assays were performed to determine if CK1a was also capable of phosphorylating S79. As seen in Figure 5a , CK1a phosphorylated Cdc25A on both S79 and S82 but not S88 in vitro. Importantly, CK1a was unable to phosphorylate S82 when S79 was changed to alanine.
To determine if CK1a also regulates S79 phosphorylation in vivo, we overproduced CK1a with Flag-Cdc25A and as seen in Figure 5b , we observed enhanced phospho-S79 levels in the presence of ectopic CK1a. In addition, D4476-treatment resulted in reduced S79 phosphorylation in vivo (Figure 5c ). These results indicate that CK1a phosphorylates Cdc25A on both S79 and S82 in vivo. Taken together, our data are supportive of a model whereby S76 phosphorylation by either Chk1 or GSK-3b primes Cdc25A for phosphorylation on S79 by CK1a and this, in turn, primes Cdc25A for S82 phosphorylation also by CK1a.
Phosphorylation-dependencies within phosphodegron of Cdc25A
Phospho-specific antibodies and Cdc25A mutant proteins were used to determine phosphorylation dependencies within the phosphodegron of Cdc25A. Phosphorylation of S76 did not require prior phosphorylation of S79, T80, S82 or S88 (Figure 6a ) and phosphorylation of S88 was independent of all other phosphorylation sites, including S76 (Figure 6b ). Phosphorylation of S82 was dependent on S76 (Figure 6c , lane 2) and S79 (lane 3) but did not require S88 (lane 6). As seen in Figure 6d , phosphorylation of S79 was dependent on S76 (lane 2) but did not require S82 (lane 5) or S88 (lane 6).
The Cdc25A phosphorylation-site mutants were also used to determine which residues are required for Figure 4 CK1a regulates S82 phosphorylation in vivo. (a) WT and mutant forms of Cdc25A were purified as GST fusion proteins from bacteria and kinase assays were performed in vitro in the presence of CK1. Reaction products were resolved by SDS-PAGE and analyzed by western blotting for the indicated proteins. (b) HeLa cells transfected with plasmids encoding either CK1a or V5-LacZ for 20 h were treated with 50 mM MG132 for 4 h, lysed and analyzed by western blotting. (c) MDA-MB-231 cells transfected with plasmids encoding tagged forms of Cdc25A and b-TrCP and untagged CK1a for 20 h were lysed and resolved directly by SDS-PAGE (WCE) or were incubated first with Myc agarose to precipitate b-TrCP. Precipitates were then resolved by SDS-PAGE followed by western blotting. (d) HeLa cells transfected with plasmids encoding V5-LacZ (lane 1) or CK1a (lane 2) for 20 h were treated with 10 mg/ml cycloheximide (CHX) for 15 min in the presence or absence of MG132 (50 mM). Lysates were prepared and analyzed for the indicated proteins by western blotting. (e) HeLa cells transfected with plasmids encoding Flag-Cdc25A for 20 h were mock-irradiated or exposed to 10 Gy IR followed by D4476 (75 mM) for 30 min. Lysates were prepared and analyzed by western blotting. (f) HeLa Tet-on Cdc25A-FLuc cells were cultured in media containing 2 mg/ml Dox for 16 h. Cells were then placed in Dox-free media and exposed to 10 Gy IR in the presence of 10 mg/ml cycloheximide together with either DMSO or D4476 (75 mM). Lysates were prepared at the indicated times after IR and were analyzed by western blotting for the indicated proteins. -10) , the S79A (lanes 11-15) and S82A (lanes 16-20) mutants, but not the S88A (lanes 21-25) mutant protein, exhibited an extended half-life in vivo (Figure 6f ). These results show that S76, S79 and S82 are the key regulatory residues that mediate recognition of Cdc25A by b-TrCP.
Discussion
Orderly progression through the mammalian cell division cycle requires that the abundance of the Cdc25A protein phosphatase be tightly controlled. This is accomplished by two distinct E3 ligase complexes that target Cdc25A for ubiquitin-mediated proteolysis at distinct phases of the cell division cycle. SCF b-TrCP operates throughout interphase to regulate Cdc25A abundance whereas APC Cdh1 operates during mitotic exit to facilitate Cdc25A degradation (Donzelli et al., 2002; Jin et al., 2003; Busino et al., 2004) . Binding of b-TrCP to its target substrates typically requires phosphorylation to create a phosphodegron recognition motif (Nash et al., 2001) . Although S76 phosphorylation is required for Cdc25A proteolysis, it does not participate directly in b-TrCP binding (Busino et al., 2003; Jin et al., 2003) . In contrast, phosphorylation of S82 has been shown to be a key mediator of b-TrCP binding (Busino et al., 2003; Jin et al., 2003) . Here, CK1 is shown to catalyze the phosphorylation of S79 and S82 and to facilitate the docking of b-TrCP to Cdc25A in vivo. This conclusion is based on the following observations: pharmacological inhibition of the CK1 family or siRNA knockdown of CK1a in particular resulted in reduced S82 phosphorylation and enhanced Cdc25A stabilization in vivo; overproduction of CK1a resulted in enhanced Cdc25A phosphorylation on S79 and S82 and enhanced b-TrCP binding in vivo; and CK1 directly phosphorylated Cdc25A on both S79 and S82 in vitro. Human Cdc25A contains two motifs that regulate its interactions with b-TrCP (pS 79 -T-D-pS 82 -G and D 215 DGFVD 220 ). These motifs are conserved in several higher eukaryotes (Supplementary Figure S5) , with the notable exception of Xenopus Cdc25A, which exclusively uses the DDGFXD motif (Kanemori et al., 2005) .
Paradoxically, CK1 was previously ruled out as a Cdc25A regulatory kinase (Jin et al., 2003) . The CK1 inhibitors used in that study (IC261 and CK1-7) are not as potent and selective as D4476 (used in our study). In addition, IC261 shows selectivity for the d and e isoforms rather than the a isoform and CK1-7 poorly penetrates cell membranes (Knippschild et al., 2005) . These properties likely account for CK1 being ruled out as a Cdc25A regulator. The CK1 family contains seven family members (a, b, g1, g2, g3, d, e ) that share similar substrate specificity in vitro. Substrate selection in vivo is regulated, in part, through subcellular localization and the presence of CK1 docking sites within specific substrates (Gross and Anderson, 1998) . Our data indicate that CK1a contributes significantly to S82 phosphorylation in vivo. Given that IC261 did not effect either S82 phosphorylation or Cdc25A stabilization at concentrations as high as 100 mM indicates that CK1d and CK1e do not significantly contribute to S82 phosphorylation in vivo. Furthermore, knockdown of CK1d, CK1e or CK1g1 did not stabilize endogenous Cdc25A (Supplementary Figure S3 ).
Cdc25A is also phosphorylated on S88 (Figures 3c  and 6b ) and there has been conflicting reports regarding the contribution made by S88 phosphorylation to interactions between b-TrCP and Cdc25A (Busino et al., 2003; Jin et al., 2003) . We show that S88 Figure 6 Phosphorylation dependencies that target Cdc25A to b-TrCP. Cells transfected with plasmids expressing WT and mutant forms of Cdc25A for 20 h were lysed and lysates were resolved by SDS-PAGE. Western blotting was performed to monitor S76 (a), S88 (b), S82 (c) and S79 (d) phosphorylation. (e) HeLa cells transfected with plasmids encoding tagged forms of Cdc25A and b-TrCP for 20 h were lysed and resolved directly by SDS-PAGE (WCE) or were incubated first with Flag agarose to precipitate Cdc25A. Precipitates were then resolved by SDS-PAGE followed by western blotting. (f) Cells expressing WT and mutant forms of Cdc25A were either lysed immediately (time ¼ 0) or were incubated in the presence of 10 mg/ml cycloheximide (CHX) for the indicated times before processing. Lysates were resolved by SDS-PAGE and subjected to western blotting.
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Y Honaker and H Piwnica-Worms phosphorylation does not rely on previous phosphorylation of S76, T80, S79 or S82 and that phosphorylation of these residues does not require S88 phosphorylation (Figures 6a-d ). Furthermore, in contrast to mutation of S76, S79 or S82, mutation of S88 does not impair b-TrCP binding to Cdc25A (Figure 6e ) nor alter the half-life of Cdc25A in vivo (Figure 6f ). The kinase(s) that phosphorylates Cdc25A on S88 has not been identified. We observed that treatment of cells with SB212190 (p38 inhibitor) or U0126 (MEK1/2) inhibitor but not LiCl (GSK-3b inhibitor) or roscovitine (Cdk inhibitor) reduced phosphorylation of Cdc25A on S88 (data not shown). This suggests that the mitogenactivated protein kinase (MAPK) signaling pathways may regulate S88 phosphorylation in vivo.
Our data are supportive of a model whereby S76 phosphorylation by either Chk1 or GSK-3b primes Cdc25A for subsequent phosphorylation on S79 by CK1 and this, in turn, primes Cdc25A for S82 phosphorylation also by CK1. This conclusion is based on the phosphorylation dependencies observed with various Cdc25A mutant proteins in vivo ( Figure 6 ) and phosphorylation assays performed in vitro with purified proteins (Figures 4a and 5a ). In the case of GSK-3b phosphorylation of S76, prior phosphorylation of T80 is required and this can be catalyzed by Plk3 (Kang et al., 2008) . Hierarchical phosphorylation of S76 ( þ /ÀT80), S79 and S82 facilitates the binding of b-TrCP to Cdc25A to facilitate the ubiquitin-mediated destruction of Cdc25A (Figure 7) .
This study identifies CK1 (CK1a) as the long soughtafter protein kinase that creates a Cdc25A phosphodegron to enable b-TrCP to bind to and facilitate Cdc25A destruction during interphase and in response to genotoxic stress. In general, the CK1 kinases are constitutively active. Thus, the requirement for a priming phosphorylation by another kinase imposes restrictions on the ability of CK1 to facilitate the destruction of Cdc25A and thereby impact cell-cycle progression. One advantage of using multiple phosphorylation events, multiple kinases and multiple E3 ligases to regulate Cdc25A may be to guarantee a flexible regulation of its levels to impose different thresholds of Cdk activity in response to both the external and internal environment. The fact that Cdc25A is primed by at least two kinases (one of which also requires substrate priming) and that the priming kinases are regulated by distinct signaling pathways, allows diverse cues to feed into the Cdc25A regulatory pathway to control cell division. For example, priming of Cdc25A by GSK-3b enables regulation of the cell division cycle by extrinsic signals that impact the phosphatidylinositol-3-kinase and MAPK pathways, whereas priming of Cdc25A by Chk1 facilitates regulation of the cell division cycle in the S and G2 phases by intrinsic checkpoint pathways that respond to replication stress and DNA damage. Whether CK1 activity is also regulated in this pathway remains to be determined. A recent report indicated that NEK11 phosphorylates Cdc25A on S79, S82 and S88 and regulates Cdc25A degradation during S and G2 phases (Melixetian et al., 2009) . Paradoxically, S82 does not reside within a consensus motif for NEK11 phosphorylation and we have been unable to detect S82 phosphorylation when full-length NEK11 is incubated with full-length Cdc25A in vitro under conditions where MBP is robustly phosphorylated by NEK11 (data not shown). Contrary to our findings and those reported previously , Melixetian et al. (2009) did not observe an absolute dependency of S82 phosphorylation by NEK11 in vitro on prior S76 phosphorylation. Future experiments are required to resolve these discrepancies.
Materials and methods

Cell lines and reagents
HeLa cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% bovine growth serum (Thermo Scientific-Hyclone, Logan, UT, USA), 1 mM glutamine and 100 U/ml each of penicillin and streptomycin. HeLa Tet-on cells (BD Biosciences-Clontech, San Jose, CA, USA) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% Tet system approved fetal bovine serum (Clontech), 1 mM glutamine, 100 U/ml each of penicillin and streptomycin and Geneticin (100 mg/ml; Clontech). HeLa Tet-on Cdc25A-FLuc stable cells were cultured in the above media plus Figure 7 Hierarchical phosphorylation regulates destruction of Cdc25A during interphase and in response to genotoxic stress. S76 phosphorylation by either Chk1 in the S/G2 phases of the cell cycle or by GSK-3b in the G1/S phases primes Cdc25A for subsequent phosphorylation on S79 by CK1 and this, in turn, primes Cdc25A for S82 phosphorylation also by CK1. In the case of GSK-3b phosphorylation of S76, prior phosphorylation of T80 is required and this can be catalyzed by Plk3. Hierarchical phosphorylation of S76 ( þ /ÀT80), S79 and S82 enables binding of b-TrCP to Cdc25A to facilitate its ubiquitin-mediated proteolysis during interphase and in response to genotoxic stress. Inactivation of GSK-3b in various cancer cells through constitutive activation of the PI3K or MAPK pathways accounts for Cdc25A overproduction in a subset of tumors (Cohen and Frame, 2001; Doble and Woodgett, 2003; Zhou et al., 2004; Kang et al., 2008) . One advantage of using multiple phosphorylation events, multiple kinases and multiple E3 ligases to regulate Cdc25A may be to guarantee a flexible regulation of its levels to impose different thresholds of Cdk activity in response to both the external and internal environment.
Hierarchical phosphorylation of Cdc25A by CK1a Y Honaker and H Piwnica-Worms hygromycin B (200 mg/ml; Invitrogen). MDA-MB-231 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% bovine growth serum, 1 mM glutamine, 1 mM sodium pyruvate and 100 U/ml each of penicillin and streptomycin. MG132 and cycloheximide (Sigma Chemical Co., St Louis, MO, USA) were dissolved in dimethyl sulfoxide and 1 Â phosphate-buffered saline, respectively. Kinase inhibitors used in this study include D4476, IC261, Go¨6976, TBB and KN-93 (Calbiochem, San Diego, CA, USA); UCN-01 (Sigma Chemical Co.) and AZD7762 (Zabludoff et al., 2008) (Axon Medchem BV, Groningen, Netherlands). D4476 was prepared as described (Rena et al., 2004) .
Antibodies
Monoclonal anti-Cdc25A antibodies (Ab-3, Thermo Fisher Scientific-Neomarkers, Fremont, CA, USA, and Ab2357, Abcam, Cambridge, MA, USA) were used to detect human Cdc25A. Other antibodies used in this study include anti-actin (Sigma Chemical Co), anti-Myc (A-14 and 9E-10; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-b-Catenin (BD Biosciences), anti-CK1a (C-19; Santa Cruz Biotechnology), anti-phospho-S45 b-Catenin (Biosource, Camarillo, CA, USA), anti-Chk1 (G4; Santa Cruz Biotechnology) and anti-pS317 Chk1 (Cell Signaling Technology, Danvers, MA, USA). Antibodies specific for Cdc25A phosphorylated on T80 and S123 were generated by immunizing rabbits with the coupled phosphopeptides C-GSSES-pT-DSGFC and C-LKRSH-pS-DSLD, respectively (Kang et al., 2008) . Antibodies specific for Cdc25A phosphorylated on S76 (C-NSNLQRMG-pS-SEST), S79 (MGSSE-pS-TDSGFC), S82 (C-SESTD-pS-GFCLD) and S88 (C-GFCLD-pS-PGPLD) were generated by immunizing rabbits with the indicated phosphopeptides followed by affinity purification (Abgent, San Diego, CA, USA). Bound primary antibodies were reacted with horseradish peroxidaseconjugated goat anti-mouse antibody (Jackson Laboratory, Bar Harbor, ME, USA), horseradish peroxidase-conjugated goat anti-rabbit antibody (Zymed, San Francisco, CA, USA), or horseradish peroxidase-conjugated rabbit anti-goat antibody (Zymed) and detected by enhanced chemiluminescence (GE Healthcare Life Sciences, Piscataway, NJ, USA).
Peptide competition
Cell lysates prepared from control cells and cells overproducing Flag-Cdc25A(WT) were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose followed by incubation in Blocking buffer (5% milk/1 Â TBST). HPLC purified peptides (Tufts University Core Facility, Boston, MA, USA) were incubated with 2 mg/ml of phospho-antibodies at concentrations between 4 and 40 mg/ml in 1 Â TBST overnight at 4 1C. Western blotting was then performed.
Expression plasmids
Generation of pcDNA3-Myc-Cdc25A-FLuc: the stop codon of Cdc25A was eliminated and an XbaI site was inserted at the C terminus of Cdc25A. The resulting plasmid pcDNA3-Myc-Cdc25A (XbaI) was digested with XbaI and XhoI and ligated to sequences encoding codon-optimized firefly luciferase (FLuc) that had been isolated as an XbaI-XhoI fragment from the pGL-3 control plasmid (Promega, Madison, WI, USA). Sequences encoding Cdc25A-FLuc but lacking the Myc-tag were isolated from pcDNA3-Myc-Cdc25A-FLuc and subcloned into pTRE-Tight, a tetracycline-regulated expression plasmid (Clontech) to generate pTRE-Tight-Cdc25A-FLuc. Cdc25A serine-to-alanine mutants were generated using the QuikChange XL site-directed mutagenesis kit (Agilent Technologies, La Jolla, CA, USA) and all the mutations were verified by DNA sequencing. Plasmids encoding CK1a and Myc-b-TrCP1 were provided by Dr Jiandong Chen (Chen et al., 2005) and Dr Binhua P Zhou (Zhou et al, 2004) , respectively.
Generation of HeLa Tet-on Cdc25A-FLuc stable cell lines and bioluminescence imaging pTRE-Tight-Cdc25A-FLuc was co-transfected with a selection plasmid pTK-Hyg (Clontech) into HeLa Tet-on cells using Lipofectamine 2000 (Invitrogen). After 24 h, we trypsinized and seeded cells into 10-cm tissue culture dishes. Selection media containing hygromycin B was added 24 h later. Media was changed every 3 days until the drug-resistant colonies became visible. Cells were incubated with D-Luciferin (150 mg/ml in phosphate-buffered saline; BIOSYNTH International) at 37 1C for 10 min followed by imaging using an IVIS 100 imaging system (Caliper Life Sciences, Hopkinton, MA, USA). Luciferase activity (photons/s/cm 2 /steradian) was quantitated using Living Image Software (Caliper Life Sciences). Those colonies that scored positive for bioluminescence were eliminated. Cells were then rinsed in phosphate-buffered saline and incubated in culture media containing 2 mg/ml of doxycycline (Dox; Clontech). After 24 h, we added D-Luciferin to the media and colonies were re-imaged. Colonies that displayed Dox-inducible bioluminescence were isolated and expanded for further analysis. The stable cell line was maintained in selection medium containing hygromycin B and Geneticin.
Kinase assays
Wild-type and mutant forms of Cdc25A were produced in bacteria as GST-fusion proteins and purified as described previously (Chen et al., 2003) . The elution of GST-Cdc25A proteins was performed as described (Kang et al., 2008) . CK1 (100 ng; GST-CK1a from Invitrogen or GST-CK1d from Sigma Chemical Co.) was diluted in kinase reaction buffer (50 mM Tris-HCl (pH 7.4), 2 mM DTT, 10 mM MgCl 2 and 120 mM ATP) followed by the addition of 1 mg soluble GST-Cdc25A. Reactions were incubated at 30 1C for 30 min, boiled in 1 Â loading buffer at 95 1C for 10 min and then resolved by SDS-PAGE followed by western blotting.
Transfection
Approximately 1 Â 10 6 HeLa cells were seeded in p60 plates 16-20 h before transfection. Cells at 95% confluence were transfected with 2-4 mg plasmids using Lipofectamine 2000. After 24 h of transfection, we harvested or subjected cells to the indicated treatments before harvest and analysis. For RNAi transfection, we seeded HeLa cells (3 Â 10 5 ) in p60 dishes 20 h before transfection. Cells were transfected with 50 nM CK1a, GSK-3b (Dharmacon, Lafayette, CO, USA) or Chk1 siRNA (Zhao et al., 2002) when they reached 20-30% confluency using DharmaFECT 1 or 3 (Dharmacon). After 48 h of transfection, we treated cells as indicated and then harvested them for western blotting. Scrambled siRNA or luciferase siRNA (GL3; Dharmacon) was used as transfection controls. For half-life experiments, we incubated siRNAtransfected cells with 10 mg/ml cycloheximide 48 h after siRNA-transfection. Cells were harvested at various times after cycloheximide treatment and analyzed by western blotting. MG132 additions were made 48 h after siRNA transfection and cells were harvested 2 h later.
